| Date | Time | Source | Headline | Symbol | Company |
| 01/17/2007 | 4:01PM | PR Newswire (US) | CV Therapeutics to Announce 2006 Fourth Quarter and Year End Financial Results on Thursday, February 8, 2007 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 01/03/2007 | 7:20PM | PR Newswire (US) | CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 12/20/2006 | 4:01PM | PR Newswire (US) | CV Therapeutics Files Application for European Marketing Approval of Ranolazine for Treatment of Chronic Angina | NASDAQ:CVTX | CV Therapeutics (MM) |
| 12/04/2006 | 7:00AM | PR Newswire (US) | Regadenoson Meets Primary Endpoint in Second Phase 3 Clinical Trial | NASDAQ:CVTX | CV Therapeutics (MM) |
| 12/04/2006 | 7:00AM | PR Newswire (US) | Regadenoson Meets Primary Endpoint in Second Phase 3 Clinical Trial | NASDAQ:CVTX | CV Therapeutics (MM) |
| 11/13/2006 | 5:58PM | PR Newswire (US) | CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 10/31/2006 | 4:01PM | PR Newswire (US) | CV Therapeutics Reports 2006 Third Quarter Financial Results | NASDAQ:CVTX | CV Therapeutics (MM) |
| 10/26/2006 | 6:00PM | PR Newswire (US) | CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2006 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 10/17/2006 | 7:01PM | PR Newswire (US) | CV Therapeutics to Announce Third Quarter Financial Results on Tuesday, October 31, 2006 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 10/11/2006 | 8:00AM | PR Newswire (US) | CV Therapeutics Ending Co-Promotion of ACEON(R) (perindopril erbumine) Tablets | NASDAQ:CVTX | CV Therapeutics (MM) |
| 10/06/2006 | 9:00AM | PR Newswire (US) | Affymax Appoints Daniel K. Spiegelman to Board of Directors | NASDAQ:CVTX | CV Therapeutics (MM) |
| 10/05/2006 | 8:00AM | PR Newswire (US) | CV Therapeutics Receives Notices of Allowance From U.S. Patent and Trademark Office and European Patent Office for Drug-Eluting | NASDAQ:CVTX | CV Therapeutics (MM) |
| 09/27/2006 | 6:00PM | PR Newswire (US) | CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 09/26/2006 | 8:00AM | PR Newswire (US) | CV Therapeutics Completes MERLIN TIMI-36 Study | NASDAQ:CVTX | CV Therapeutics (MM) |
| 08/24/2006 | 8:00AM | PR Newswire (US) | CV Therapeutics Announces Seven Abstracts Accepted for Presentation at the European Society of Cardiology/World Congress of Car | NASDAQ:CVTX | CV Therapeutics (MM) |
| 08/18/2006 | 8:00AM | PR Newswire (US) | CV Therapeutics Announces Exercise of Over-Allotment Option of 1,350,000 Shares of Common Stock | NASDAQ:CVTX | CV Therapeutics (MM) |
| 08/16/2006 | 8:00AM | PR Newswire (US) | CV Therapeutics Announces Pricing of Public Offering of 9,000,000 Shares of Common Stock | NASDAQ:CVTX | CV Therapeutics (MM) |
| 08/14/2006 | 8:14AM | PR Newswire (US) | CV Therapeutics Announces Public Offering of Common Stock | NASDAQ:CVTX | CV Therapeutics (MM) |
| 08/03/2006 | 5:05PM | PR Newswire (US) | CV Therapeutics Reports 2006 Second Quarter Financial Results | NASDAQ:CVTX | CV Therapeutics (MM) |
| 08/01/2006 | 8:00AM | PR Newswire (US) | JCI Publishes Preclinical Study Evaluating Potential Ability of CVT-6883 for the Treatment of Pulmonary Conditions | NASDAQ:CVTX | CV Therapeutics (MM) |
| 07/20/2006 | 5:00PM | PR Newswire (US) | CV Therapeutics to Announce 2006 Second Quarter Financial Results on Thursday, August 3, 2006 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 06/22/2006 | 8:00AM | PR Newswire (US) | CV Therapeutics Acquires Rights to Ranolazine in Asia | NASDAQ:CVTX | CV Therapeutics (MM) |
| 06/21/2006 | 8:00AM | PR Newswire (US) | MERLIN TIMI-36 Study Design Published in American Heart Journal | NASDAQ:CVTX | CV Therapeutics (MM) |
| 06/19/2006 | 8:00AM | PR Newswire (US) | JACC Publishes ERICA Trial Results Showing Ranexa(R) Reduces Angina Frequency and Nitroglycerin Consumption | NASDAQ:CVTX | CV Therapeutics (MM) |
| 06/14/2006 | 6:00PM | PR Newswire (US) | CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 06/12/2006 | 9:00AM | PR Newswire (US) | PTC Therapeutics and CV Therapeutics Announce Collaboration and License Arrangement | NASDAQ:CVTX | CV Therapeutics (MM) |
| 06/07/2006 | 8:00AM | PR Newswire (US) | CV Therapeutics Completes Enrollment of Second Regadenoson Phase 3 Trial | NASDAQ:CVTX | CV Therapeutics (MM) |
| 05/25/2006 | 6:45PM | PR Newswire (US) | CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 05/25/2006 | 8:00AM | PR Newswire (US) | CV Therapeutics Announces Completion of MERLIN TIMI-36 Enrollment | NASDAQ:CVTX | CV Therapeutics (MM) |
| 05/22/2006 | 2:00PM | PR Newswire (US) | Seven Summits Research Releases Comments on MOT, BSX, MAT, KR, and CVTX | NASDAQ:CVTX | CV Therapeutics (MM) |